Twyman Roy Ervin 4

What Happened

• Roy Ervin, a director of AC Immune SA (ACIU), was granted compensation awards on June 11, 2026: 16,568 restricted share units (RSUs) and share options covering 38,889 common shares. Both grants were reported with an acquisition price of $0.00 (i.e., awards/compensation), so reported cash value on the Form 4 is $0. The 38,889-option award is a derivative grant (options), not an exercised option.

Key Details

• Transaction date(s): June 11, 2026. Report filed June 15, 2026 (appears timely per standard Form 4 deadlines).
• Price: $0.00 for both the RSU grant and the option grant (reported as awards).
• Vesting / restrictions: RSUs granted under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). The 38,889 share options will fully vest on June 10, 2027 (per filing footnote).
• Shares owned after transaction: the Form notes that it "includes 66,556 common shares underlying outstanding restricted share units" (footnote), but does not list a single total beneficial ownership number on the provided summary.
• Footnotes: F1 = 16,568 RSU grant under SOIP; F3 = 38,889 share options granted, vesting fully on June 10, 2027; F2 = includes 66,556 common shares underlying outstanding RSUs.
• Transaction code: A = Award/Grant.

Context

• RSUs and option grants are compensation, not open-market purchases or sales. RSUs typically convert to shares upon vesting; options give the holder the right to buy shares in the future if exercised. These grants signal company compensation actions but are not direct buys or sells of stock by the insider.